Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.39 |
| ▸ | FABP4 | P15090 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 2/20 | 0.37 |
| ▸ | GABRD | O14764 | 2/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.37 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.37 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.37 |
| ▸ | GABRE | P78334 | 2/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2008152 | 0.86 | SLC6A12 (0.36) | POLBSLC6A12FABP4FABP5LMNA | |
| SCHEMBL18921611 | 0.80 | HCRTR1 (0.38) | KEAP1NFE2L2SLC6A12FABP4FABP5 | |
| SCHEMBL4650346 | 0.80 | TUBB4A (0.47) | POLBSLC6A12LMNASMN1; SMN2CYP1A2 | |
| Nitrous Acid SCHEMBL28169420 | 0.77 | GABRP (0.47) | POLBKEAP1NFE2L2GABRPGABRD | |
| SCHEMBL1969860 | 0.76 | KMT2A (0.53) | SLC6A12LMNAHTTSMN1; SMN2CYP1A2 | |
| SCHEMBL28087809 | 0.74 | DHODH (0.39) | POLBKEAP1NFE2L2FABP4FABP5 | |
| SCHEMBL1969832 | 0.74 | HSD11B1 (0.57) | LMNAHTTALDH1A1KMT2A | |
| SCHEMBL56617 | 0.72 | SMN1; SMN2 (0.50) | POLBKEAP1NFE2L2SLC6A12SORT1 | |
| SCHEMBL29378242 | 0.72 | SMN1; SMN2 (0.50) | POLBKEAP1NFE2L2SLC6A12SORT1 | |
| SCHEMBL28187406 | 0.72 | KDM4E (0.41) | POLBHTTSMN1; SMN2CYP1A2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1718613-B1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2008-09-03 | — | — | EP | disclosed |
| EP-1735301-A1 | PYRIDINE DERIVATIVES AS CANNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-12-27 | — | — | EP | disclosed |
| EP-1718613-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005080342-A1 | PYRIDINE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-09-01 | — | — | WO | disclosed |
| WO-2005075464-A1 | PYRIDINE DERIVATIVES AS CONNABINOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280868-A1 | Pyridine Derivatives and Their Use as Cb2 Receptor Modulators | CNR2, CNR1, TRPV1 | POLB 4348/4885KEAP1 1910/4885NFE2L2 970/4885 |
| US-20080280952-A1 | Pyridine Derivatives as Connabinoid Receptor Modulators | CNR1, CNR2, P2RY1 | POLB 4047/4885KEAP1 1340/4885NFE2L2 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.